[go: up one dir, main page]

AU2016266708B2 - Combination of an anti-CD19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof - Google Patents

Combination of an anti-CD19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof Download PDF

Info

Publication number
AU2016266708B2
AU2016266708B2 AU2016266708A AU2016266708A AU2016266708B2 AU 2016266708 B2 AU2016266708 B2 AU 2016266708B2 AU 2016266708 A AU2016266708 A AU 2016266708A AU 2016266708 A AU2016266708 A AU 2016266708A AU 2016266708 B2 AU2016266708 B2 AU 2016266708B2
Authority
AU
Australia
Prior art keywords
lymphoma
ser
seq
sequence
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016266708A
Other languages
English (en)
Other versions
AU2016266708A1 (en
Inventor
Rainer Boxhammer
Jan Endell
Mark Winderlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2016266708A1 publication Critical patent/AU2016266708A1/en
Application granted granted Critical
Publication of AU2016266708B2 publication Critical patent/AU2016266708B2/en
Priority to AU2022202796A priority Critical patent/AU2022202796B2/en
Priority to AU2024201029A priority patent/AU2024201029A1/en
Assigned to INCYTE CORPORATION reassignment INCYTE CORPORATION Request for Assignment Assignors: MORPHOSYS AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2016266708A 2015-05-26 2016-05-25 Combination of an anti-CD19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof Active AU2016266708B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022202796A AU2022202796B2 (en) 2015-05-26 2022-04-28 Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
AU2024201029A AU2024201029A1 (en) 2015-05-26 2024-02-16 Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15169124.3 2015-05-26
EP15169124 2015-05-26
EP15196860 2015-11-27
EP15196860.9 2015-11-27
PCT/EP2016/061744 WO2016189014A1 (fr) 2015-05-26 2016-05-25 Combinaison d'un anticorps anti-cd19 et d'un inhibiteur de la tyrosine kinase de bruton et utilisations de ceux-ci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202796A Division AU2022202796B2 (en) 2015-05-26 2022-04-28 Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof

Publications (2)

Publication Number Publication Date
AU2016266708A1 AU2016266708A1 (en) 2017-11-16
AU2016266708B2 true AU2016266708B2 (en) 2022-02-03

Family

ID=56084030

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016266708A Active AU2016266708B2 (en) 2015-05-26 2016-05-25 Combination of an anti-CD19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
AU2022202796A Active AU2022202796B2 (en) 2015-05-26 2022-04-28 Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
AU2024201029A Pending AU2024201029A1 (en) 2015-05-26 2024-02-16 Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022202796A Active AU2022202796B2 (en) 2015-05-26 2022-04-28 Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
AU2024201029A Pending AU2024201029A1 (en) 2015-05-26 2024-02-16 Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof

Country Status (23)

Country Link
US (3) US10617691B2 (fr)
EP (2) EP3603672A1 (fr)
JP (4) JP6916741B2 (fr)
KR (1) KR102809079B1 (fr)
CN (2) CN107660151B (fr)
AU (3) AU2016266708B2 (fr)
CA (1) CA2986175A1 (fr)
CY (1) CY1122298T1 (fr)
DK (1) DK3302550T3 (fr)
ES (1) ES2754431T3 (fr)
HK (1) HK1251152B (fr)
HR (1) HRP20192100T1 (fr)
HU (1) HUE046328T2 (fr)
IL (2) IL255377B (fr)
LT (1) LT3302550T (fr)
PL (1) PL3302550T3 (fr)
PT (1) PT3302550T (fr)
RS (1) RS59605B1 (fr)
RU (1) RU2756010C2 (fr)
SI (1) SI3302550T1 (fr)
SM (1) SMT201900647T1 (fr)
WO (1) WO2016189014A1 (fr)
ZA (1) ZA201707867B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2710042A2 (fr) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
DK3337506T3 (da) 2015-08-21 2021-09-06 Morphosys Ag Kombinationer og anvendelser deraf
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
SG10202104036QA (en) 2016-10-28 2021-05-28 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
CN110248677B (zh) * 2017-01-05 2023-05-16 上海煦顼技术有限公司 人源化抗cd19抗体及其与嵌合抗原受体的用途
CN110945028B (zh) 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
EP3847196A4 (fr) * 2018-09-07 2023-01-04 ITabMed (HK) Limited Protéines de liaison à un antigène bispécifiques et leurs utilisations
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2022005033A (es) * 2019-10-31 2022-09-09 Morphosys Ag Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.
US20240156863A1 (en) * 2019-10-31 2024-05-16 Morphosys Ag Sequential anti-cd19 therapy
WO2022115762A1 (fr) * 2020-11-30 2022-06-02 Incyte Corporation Polythérapie faisant appel à un anticorps anti-cd19 et à du parsaclisib
WO2022115120A1 (fr) * 2020-11-30 2022-06-02 Incyte Corporation Polythérapie comprenant un anticorps anti-cd19 et le parsaclisib
WO2024037594A1 (fr) * 2022-08-19 2024-02-22 Beijing Innocare Pharma Tech Co., Ltd. Traitement combiné avec de l'orelabrutinib et du tafasitamab
KR102655236B1 (ko) 2024-01-02 2024-04-08 한화시스템(주) 빔 조향범위 확장 구조를 가지는 저궤도 통신위성 배열안테나

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CN1592645A (zh) 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1648512A4 (fr) 2003-07-31 2009-01-21 Immunomedics Inc Anticorps anti-cd19
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
ES2365046T3 (es) * 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
ME01786B (me) 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
CN103694349A (zh) 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
EP2526934B1 (fr) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
EP3392273A1 (fr) 2007-05-30 2018-10-24 Xencor, Inc. Procédés et compositions pour inhiber des cellules exprimant cd32b
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
WO2010095031A2 (fr) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Anticorps humanisés qui se fixent au cd19 et leurs utilisations
CA2765080C (fr) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methodes de traitement de la leucemie lymphocytique chronique
WO2011147834A1 (fr) 2010-05-26 2011-12-01 Roche Glycart Ag Anticorps contre cd19 et utilisations associées
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
EP2409993A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré
EP2409712A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré
EP2524929A1 (fr) 2011-05-17 2012-11-21 Sanofi Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B
KR20180084153A (ko) 2011-06-10 2018-07-24 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
HRP20220228T1 (hr) * 2011-08-16 2022-05-13 Morphosys Ag Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
HUE058855T2 (hu) 2011-08-16 2022-09-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
AR092790A1 (es) * 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
EP2890691B1 (fr) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Dérivés de benzimidazole en tant qu'inhibiteurs d'itk
WO2014113932A1 (fr) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Inhibiteurs de btk

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEI WU ET AL, "Novel agents for chronic lymphocytic leukemia", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, (2013-05-16), vol. 6, no. 1, doi:10.1186/1756-8722-6-36, ISSN 1756-8722, page 36 *

Also Published As

Publication number Publication date
CN107660151A (zh) 2018-02-02
HUE046328T2 (hu) 2020-03-30
WO2016189014A1 (fr) 2016-12-01
AU2022202796B2 (en) 2023-11-23
RS59605B1 (sr) 2020-01-31
IL287433A (en) 2021-12-01
US20240009196A1 (en) 2024-01-11
PL3302550T3 (pl) 2020-02-28
US10617691B2 (en) 2020-04-14
CY1122298T1 (el) 2021-01-27
EP3603672A1 (fr) 2020-02-05
HRP20192100T1 (hr) 2020-02-21
CA2986175A1 (fr) 2016-12-01
RU2017143166A3 (fr) 2019-11-28
EP3302550A1 (fr) 2018-04-11
JP2018516905A (ja) 2018-06-28
KR102809079B1 (ko) 2025-05-21
JP2023058502A (ja) 2023-04-25
LT3302550T (lt) 2019-11-11
NZ736820A (en) 2025-02-28
AU2022202796A1 (en) 2022-05-19
AU2016266708A1 (en) 2017-11-16
JP6916741B2 (ja) 2021-08-11
CN114601931A (zh) 2022-06-10
CN114601931B (zh) 2023-09-01
CN107660151B (zh) 2022-03-11
RU2017143166A (ru) 2019-06-27
ES2754431T3 (es) 2020-04-17
DK3302550T3 (da) 2019-11-04
SI3302550T1 (sl) 2020-01-31
SMT201900647T1 (it) 2020-01-14
US20200206228A1 (en) 2020-07-02
EP3302550B1 (fr) 2019-08-28
JP2021152029A (ja) 2021-09-30
JP2025016532A (ja) 2025-02-04
PT3302550T (pt) 2019-11-26
KR20180004286A (ko) 2018-01-10
RU2756010C2 (ru) 2021-09-24
IL255377B (en) 2021-12-01
IL255377A (en) 2018-02-28
US20180153892A1 (en) 2018-06-07
AU2024201029A1 (en) 2024-03-14
ZA201707867B (en) 2021-03-31
HK1251152B (en) 2020-04-24

Similar Documents

Publication Publication Date Title
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
AU2022202800B2 (en) Combinations and uses thereof
HK1251152A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK40023127A (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK40069168A (en) Combinations and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INCYTE CORPORATION

Free format text: FORMER OWNER(S): MORPHOSYS AG